```
     (FILE 'HOME' ENTERED AT 16:10:43 ON 01 MAR 96)

     FILE 'CA' ENTERED AT 16:10:54 ON 01 MAR 96
L1         32026 S PHOSPHATIDYLCHOLIN?
L2         33424 S TRIGLYCERID?
L3         14893 S CHOLAT? OR CHOLAN? OR BILE ACID?
L4            16 S L1 AND L2 AND L3
L5           530 S L1 AND L3
L6          1768 S ENDOTOXEM?
L7            10 S L1 AND L6
L8            17 S L2 AND L6
L9             9 S L3 AND L6
L10           36 S L7 OR L8 OR L9

=> s l4 or l10

L11           52 L4 OR L10

=> d l11 1-52 bib ab kw
```

```
     (FILE 'USPAT' ENTERED AT 14:56:47 ON 01 MAR 96)
L1          1197 S PHOSPHATIDYLCHOLIN?
L2          9021 S TRIGLYCERID?
L3          1883 S CHOLÀT? OR CHOLAN? OR BILE ACID?
L4            72 S L1 AND L3
L5            25 S L4 AND L2
L6           136 S ENDOTOXEM?
L7            19 S L1 AND L6
L8             9 S L2 AND L6
L9             6 S L3 AND L6
L10           31 S L7 OR L8 OR L9
=>
```

US PAT NO: 5,223,285 [IMAGE AVAILABLE] L10: 22 of 31
DATE ISSUED: Jun. 29, 1993
TITLE: Nutritional product for pulmonary patients
INVENTOR: Stephen J. DeMichele, Dublin, OH
Timothy J. Gregory, Gahanna, OH
ASSIGNEE: Abbott Laboratories, Abbott Park, IL (U.S. corp.)
APPL-NO: 07/860,857
DATE FILED: Mar. 31, 1992
ART-UNIT: 132
PRIM-EXMR: Carolyn Paden
LEGAL-REP: Lonnie R. Drayer, Donald O. Nickey

US PAT NO: 5,223,285 [IMAGE AVAILABLE] L10: 22 of 31

GE AVAILABLE] L5: 25 of 25

DATE ISSUED: Feb. 5, 1985

TITLE: Process for filling pharmaceutical products containing phospholipides and highly viscous at room temperature, into hard capsules

INVENTOR: Manfred Durr, Pulheim-Brauweiler, Federal Republic of Germany
Hans-Ulrich Fribolin, Neuss, Federal Republic of Germany

ASSIGNEE: A. Nattermann & Cie GmbH, Cologne, Federal Republic of Germany (foreign corp.)

APPL-NO: 06/269,525

DATE FILED: Jun. 2, 1981

ART-UNIT: 233

PRIM-EXMR: A. J. Heinz

LEGAL-REP: Pearne, Gordon, Sessions, McCoy, Granger & Tilberry

US PAT NO: 4,497,157

US PAT NO:	5,032,585 [IMAGE AVAILABLE] L5: 16 of 25
DATE ISSUED:	Jul. 16, 1991
TITLE:	Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
INVENTOR:	Lenard M. Lichtenberger, Houston, TX (Rule 47)
ASSIGNEE:	Board of Regents, The University of Texas System, Austin, TX (U.S. corp.)
APPL-NO:	07/323,671
DATE FILED:	Mar. 15, 1989
ART-UNIT:	125
PRIM-EXMR:	Stanley J. Friedman
ASST-EXMR:	D. Gardner
LEGAL-REP:	Arnold, White & Durkee

US PAT NO: 5,134,129 [IMAGE AVAILABLE] L5: 10 of 25
DATE ISSUED: Jul. 28, 1992
TITLE: Methods employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
INVENTOR: Lenard M. Lichtenberger, Houston, TX
ASSIGNEE: Board of Regents, The University of Texas System, Austin, TX (U.S. corp.)
APPL-NO: 07/636,672
DATE FILED: Feb. 4, 1991
ART-UNIT: 125
PRIM-EXMR: Frederick E. Waddell
ASST-EXMR: Diane Gardner
LEGAL-REP: Arnold, White & Durkee

US PAT NO: 5,

US PAT NO: 5,260,284 [IMAGE AVAILABLE] L5: 6 of 25
DATE ISSUED: Nov. 9, 1993
TITLE: Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy
INVENTOR: Lenard M. Lichtenberger, Houston, TX
ASSIGNEE: Board of Regents, The University of Texas System (U.S. corp.)
APPL-NO: 07/862,841
DATE FILED: Apr. 3, 1992
ART-UNIT: 125
PRIM-EXMR: Frederick E. Waddell
ASST-EXMR: Gregory Hook
LEGAL-REP: Arnold, White & Durkee

US PAT NO: 5,260,284 [IMAGE AVAILABLE]

US PAT NO: 5,456,912 [IMAGE AVAILABLE] L5: 2 of 25
DATE ISSUED: Oct. 10, 1995
TITLE: Non-methylene interrupted fatty acids as immunomodulators
INVENTOR: J. Bruce German, Davis, CA
M. Eric Gershwin, Davis, CA
Alvin Berger, Arlington, VA
ASSIGNEE: The Regents of the University of California, Oakland, CA (U.S. corp.)
APPL-NO: 08/174,956
DATE FILED: Dec. 28, 1993
ART-UNIT: 185
PRIM-EXMR: Ronald W. Griffin
LEGAL-REP: Townsend and Townsend Khourie and Crew

US PAT NO: 5,456,912 [IMAGE AVAILA

L11 ANSWER 17 OF 52 CA COPYRIGHT 1996 ACS
AN 116:16911 CA
TI Chylomicrons can inhibit endotoxin activity in vitro
AU Eichbaum, Eldan B.; Harris, Hobart W.; Kane, John P.; Rapp, Joseph H.
CS Dep. Surg., San Francisco Veterans Affairs Med. Cent., San Francisco, CA, 94121, USA
SO J. Surg. Res. (1991), 51(5), 413-16
CODEN: JSGRA2; ISSN: 0022-4804
DT Journal
LA English
AB Because cholesterol-rich lipoproteins can neutralize the toxic activity of endotoxin, both in vitro and in vivo, the authors examd. whether ***triglyceride*** -rich chylomicrons can inhibited endotoxin activity in vitro as measured by a chromogenic Limulus assay. The effect of intact vs. heat-denatured chylomicrons on the in vitro activity of increasing concns. of Escherichia coli (055:B5) endotoxin was tested. Intact chylomicrons inhibited up to 12-fold the detection of as much as 1 .mu.g of endotoxin/mg of chylomicron ***triglyceride*** , compared to denatured chylomicrons. This study shows that chylomicrons are potent inhibitors of endotoxin activity in vitro. Because translocated endotoxin from the colon assocs. with gut-derived chylomicrons in the mesenteric lymphatics, this may represent a natural defensive mechanism against ***endotoxemia*** of enteric origin.
ST endotoxin activity chylomicron

L11 ANSWER 19 OF 52 CA COPYRIGHT 1996 ACS
AN 115:273920 CA
TI Equilibrium among lipid molecular assemblies and their surface microenvironment
AU Handa, Tetsurou
CS Fac. Pharm. Sci., Kyoto Univ., Kyoto, 606, Japan
SO Yakugaku Zasshi (1991), 111(8), 410-23
CODEN: YKKZAJ; ISSN: 0372-7750
DT Journal
LA Japanese
AB Various lipid mol. assemblies, monolayer, bilayer, emulsion particle, hexagonal II phase and micellar particle, are in dynamic equil. in an animal body. The monolayer-bilayer equil. of a mixt. of phospholipid and neutral lipid is influenced by the phase state of bilayer and mol. interaction of lipids. Neutral lipids, such as ***triglyceride*** , cholesteryl ester, ubiquinone-10 and .alpha.-tocopherol acetate form an emulsion structure with ***phosphatidylcholine*** (PC). Stable emulsion particles (neutral lipid core covered with PC monolayer) are in equil. with liposome particles (PC bilayers). This kind of equil. is important in catabolism of ***triglyceride*** -rich lipoprotein particles and artificial emulsion particles, Intralipid, in the plasma. Some other neutral lipids, such as diglyceride, menaquinone-4 and .alpha.-tocopherol induce a formation of intra- and interbilayer particles in the PC bilayer, and finally transform it to hexagonal II phase. This type of neutral lipid has been implicated in several cellular processes: vesiculation, fusion, endocytosis and exocytosis etc. More hydrophilic lipids, such as ***cholate*** , or proteins with amphipathic helixes, such as apoA-1, strongly interact with the PC bilayer and transform it to micellar particles; mixed disk micellar or high d. lipoprotein particles. The phospholipid bilayer, therefore, converts into various nonbilayer structures by interaction with neutral lipid and protein in an animal body.
ST lipid membrane micelle emulsion equil animal; phospholipid membrane micelle emulsion equil animal; lipoprotein catabolism animal

L11 ANSWER 20 OF 52 CA COPYRIGHT 1996 ACS
AN 115:206821 CA
TI Long-term feeding with structured lipid composed of medium-chain and n-3 fatty acids ameliorates endotoxic shock in guinea pigs
AU Teo, Tiew C.; Selleck, Kelley M.; Wan, Jennifer M. F.; Pomposelli, James J.; Babayan, Vigen K.; Blackburn, George L.; Bistrian, Bruce R.
CS Dep. Surg., Aberdeen R. Infirm., Aberdeen, UK
SO Metab., Clin. Exp. (1991), 40(11), 1152-9
CODEN: METAAJ; ISSN: 0026-0495
DT Journal
LA English
AB The metabolic and physiol. responses to 7-h endotoxin infusion (5.0 mg/kg h) were evaluated in guinea pigs following 6 wk of dietary enrichment with diets contg. either chem. structured lipid (SL) composed of medium-chain ***triglycerides*** (MCT) and long-chain ***triglycerides*** (LCT) in the form of n-3 polyunsatd. fatty acids (PUFAs), or safflower oil (SO), which is high in n-6 fatty acids. Plasma phospholipid fatty acid profiles, arterial blood pH, Pco2, Po2, HCO2, lactate, blood pressure, oxygen consumption, and energy expenditure were examd. Plasma phospholipid fatty acids profiles reflected dietary intake with SL-fed animals demonstrating a significantly higher n-3 to n-6 fatty acid ratio compared with SO-fed animals, SL-fed animals responded to ***endotoxemia*** with a mild metabolic acidosis with respiratory compensation, which was assocd. with moderate lactatemia (3 mmol/L). SO-fed animals developed a severe metabolic acidosis with acidemia and respiratory compensation, which was assocd. with hyperlactatemia (8 mmol/L). No differences were obsd. in blood pressure, oxygen consumption, energy expenditure, or RQ during ***endotoxemia*** between dietary groups compared with controls. Diets enriched with structured lipid composed of medium-chain and n-3 fatty acids can thus attenuate the sequelae of ***endotoxemia*** .
ST fatty acid diet endotoxin shock